Form 4: Integrated Biopharma Director and 10% Owner Granted Significant Stock Options

William H. Milmoe, a Director and 10% Owner of Integrated Biopharma Inc. (INBP), was granted 50,000 stock options with a $0.33 exercise price, vesting in four equal installments through June 2026.

Summary

• The reporting person is William H. Milmoe, who serves as a Director and 10% Owner of INTEGRATED BIOPHARMA INC (INBP).
• On June 18, 2025, Mr. Milmoe acquired 50,000 stock options (Right to Buy) in Integrated Biopharma Inc.
• Each stock option has an exercise price of $0.33.
• The stock options are set to expire on June 18, 2035.
• The 50,000 stock options will vest and become exercisable in four equal installments of 12,500 options each.
• The vesting dates are September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026.
• Following this transaction, William H. Milmoe beneficially owns 50,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director and significant owner is generally a positive signal as it aligns management's interests with shareholder value, encouraging long-term performance. It's a routine compensation event, so not overwhelmingly positive, but certainly not negative.

Positives

• The grant of stock options to a director and significant owner helps align their interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
• The multi-year vesting schedule encourages long-term commitment and performance from the reporting person.

Future Outlook

The grant of stock options with a vesting schedule extending to June 2026 indicates a long-term incentive for the reporting person, aligning their future interests with the company's performance and potential growth.

Industry Context

This Form 4 filing reports a routine equity grant to a director and significant shareholder, which is a common compensation practice across various industries, including biotechnology. Such grants are designed to incentivize long-term performance and align the interests of key personnel with those of the company's shareholders.

Comparison to Industry Standards

• The grant of 50,000 stock options to a director and 10% owner with a 10-year expiration and multi-year vesting schedule is a common practice for executive and director compensation in the biotech sector.
• This type of equity incentive is standard for aligning insider interests with company performance.
• Without specific comparable companies' compensation details, a direct quantitative comparison of the grant size relative to industry benchmarks is not feasible from this document alone.

Stakeholder Impact

• Shareholders: The grant of stock options to a director and significant owner can lead to better alignment of management's interests with shareholder value, potentially encouraging decisions that enhance long-term stock performance.

Next Steps

• The stock options will vest in four equal installments on September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026.
• William H. Milmoe may choose to exercise these options after they vest, subject to the expiration date of June 18, 2035.

Key Dates

Recommendation

Keywords

Integrated Biopharma Inc, INBP, Stock Options, Insider Transaction, Form 4, Beneficial Ownership, Director Compensation, Equity Grant, William H. Milmoe